Amylyx Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
AMLX$30.21+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $170,201 | $62,526 |
| Short-term investments | 201,161 | 284,419 |
| Accounts receivable, net | 40,050 | 15,306 |
| Inventories | 38,323 | 9,769 |
| Prepaid expenses and other current assets | 14,931 | 10,113 |
| Total current assets | 464,666 | 382,133 |
| Property and equipment, net | 2,686 | 2,611 |
| Restricted cash equivalents | 719 | 719 |
| Operating lease right-of-use assets | 3,725 | 5,524 |
| Long-term inventories | 44,957 | — |
| Other assets | 701 | 466 |
| Total assets | $517,454 | $391,453 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $22,061 | $6,257 |
| Accrued expenses | 57,724 | 38,312 |
| Operating lease liabilities, current portion | 2,257 | 2,040 |
| Total current liabilities | 82,042 | 46,609 |
| Operating lease liabilities, net of current portion | 1,980 | 4,237 |
| Total liabilities | 84,022 | 50,846 |
| Commitments and contingencies (Note 18) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized; 67,707,432 and 66,512,011 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 7 | 7 |
| Additional paid-in capital | 738,177 | 694,906 |
| Accumulated deficit | (304,949) | (354,220) |
| Accumulated other comprehensive income (loss) | 197 | (86) |
| Total stockholders’ equity | 433,432 | 340,607 |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity | $517,454 | $391,453 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.